Meeting
2014 ASCO Annual Meeting
Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL).
Authors
Caroline Houillier
APHP-CHU Pitié-Salpêtrière, Paris, France
Caroline Houillier , Sylvain Choquet , Valerie Touitou , Nadine Martin-Duverneuil , Khê Hoang-Xuan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2079)
DOI
10.1200/jco.2014.32.15_suppl.2079
Abstract #
2079
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
First Author: Tongyu Lin
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi
Poster
2020 ASCO Virtual Scientific Program
Role of high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma: A systematic review.
First Author: Shaha Nabeel